Impaired Glucose Tolerance in HIV-Positive Patients Receiving and Those Not Receiving Protease Inhibitors
Authors: Stefan Mauss
Journal: Annals of Internal Medicine (1999)

Letters19 January 1999Impaired Glucose Tolerance in HIV-Positive Patients Receiving and Those Not Receiving Protease InhibitorsStefan Mauss, MD, Eva Wolf, PhD, and Hans Jaeger, MDStefan Mauss, MDCuratorium for Immune Deficiency; Munich, GermanySearch for more papers by this author, Eva Wolf, PhDCuratorium for Immune Deficiency; Munich, GermanySearch for more papers by this author, and Hans Jaeger, MDCuratorium for Immune Deficiency; Munich, GermanySearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-130-2-199901190-00019 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Data on the incidence of diabetes mellitus in HIV-positive patients receiving protease inhibitors are conflicting (1-4). To determine the prevalence of impaired glucose tolerance and diabetes in HIV-positive patients and to identify risk factors, we retrospectively reviewed the patient charts of an HIV outpatient clinic in 1997. Antiretroviral treatment consisted of reverse transcriptase inhibitors (didanosine, lamivudine, nevirapine, stavudine, zalcitabine, and zidovudine) and protease inhibitors (indinavir, nelfinavir, ritonavir, and saquinavir). Impaired glucose tolerance was defined as a serum glucose level greater than 140 mg/dL, and diabetes was defined as a serum glucose level greater than 180 mg/mL. This ...References1. Dever LL, Oruwari PA, O'Donovan CA, Eng RH. Hyperglycemia associated with protease inhibitors in HIV-infected patients [Abstract]. Program of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, 28 September-1 October 1997. Google Scholar2. FDA Public Health Advisory. Reports of diabetes and hyperglycemia in patients receiving protease inhibitors for the treatment of human immunodeficiency virus (HIV). Washington, DC: Food and Drug Administration, 11 June 1997. Google Scholar3. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, et al . A syndrome of peripheral lipodystrophy, hyperlipidaemia, and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51-8. CrossrefMedlineGoogle Scholar4. Keruly JC, Chaisson RE, Moore RD. Diabetes and hyperglycemia in patients receiving protease inhibitors [Abstract]. Program and Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections, Chicago, 1-5 February 1998. Google Scholar5. Foster DW. Diabetes mellitus. In: Isselbacher KJ, Braunwald E, Wilson JD, Martin JB, Fauci AS, Kasper DL, eds. Harrison's Principles of Internal Medicine. 3rd ed. New York: McGraw-Hill; 1994:1979-2000. Google Scholar Author, Article, and Disclosure InformationAffiliations: Curatorium for Immune Deficiency; Munich, Germany PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoImpaired Glucose Tolerance in HIV-Infected Patients Zuhayr T. Madhun , Baha M. Arafah , and Grace A. McComsey Saquinavir-Induced Hypoglycemia in Type 2 Diabetes Oren Zimhony and David Stein Metrics Cited byChange in serum lipid profiles and glucose after switching from stavudine/lamivudine to zidovudine/lamivudine in non-nucleoside reverse transcriptase inhibitors based anti-retroviral regimens in Southern EthiopiaAntiretroviral treatment for HIV infection/AIDS and the risk of developing hyperglycemia and hyperlipidemiaManagement of Antiretroviral Treatment–Related ComplicationsEffects of lamivudine therapy on the glucose metabolism in children with chronic hepatitis B: first year follow-up resultsStimulation of Peroxisome Proliferator-Activated Receptors α and γ Blocks HIV-1 Replication and TNFα Production in Acutely Infected Primary Blood Cells, Chronically Infected U1 Cells, and Alveolar Macrophages From HIV-Infected SubjectsElectron Beam Computed Tomography for Assessment of Coronary Artery Disease in HIV-Infected Men Receiving Antiretroviral TherapyFactors Related to Lipodystrophy and Metabolic Alterations in Patients with Human Immunodeficiency Virus Infection Receiving Highly Active Antiretroviral TherapyCoronary Artery Disease and Human Immunodeficiency Virus InfectionLipodystrophy Syndrome in HIV InfectionSaquinavir-Induced Hypoglycemia in Type 2 DiabetesOren Zimhony, MD and David Stein, MDImpaired Glucose Tolerance in HIV-Infected PatientsZuhayr T. Madhun, MD, Baha M. Arafah, MD, and Grace A. McComsey, MDProtease inhibitors impair glucose tolerance 19 January 1999Volume 130, Issue 2Page: 162-163KeywordsAntiretroviralsGlucoseGlucose intoleranceHIVHyperglycemiaMedical risk factorsOutpatient clinicsPatientsProtease inhibitorsReverse transcriptase inhibitors Issue Published: 19 January 1999 Copyright & PermissionsCopyright © 1999 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...